Screener
BioCryst Pharmaceuticals BCRX Contract Liabilities
Contract Liabilities at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.
The source filing: BioCryst Pharmaceuticals’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:04 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053300
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Finance lease liabilities | 849 | 1,441 |
| Royalty financing obligations | 382,981 | 427,233 |
| Secured term loan | 395,400 | — |
| Deferred revenue | 13,461 | — |
| Total liabilities | 1,012,140 | 633,311 |
| Stockholders’ deficit: | ||
| Preferred stock, $0.01 par value; shares authorized - 5,000; no shares issued and outstanding at June 30, 2026 and December 31, 2025 | — | — |
| Common stock, $0.01 par value; shares authorized - 450,000; shares issued and outstanding – 255,265 at June 30, 2026 and 213,060 at December 31, 2025 | 2,553 | 2,131 |
Item 1. Financial Statements (Unaudited):
FAQ
- What is BioCryst Pharmaceuticals's contract liabilities?
- BioCryst Pharmaceuticals (BCRX) reported contract liabilities of $13.46M in Q2 2026.
- What does contract liabilities mean?
- Revenue collected or billed in advance of performance — deferred revenue under ASC 606 terminology, representing future revenue obligations.
Ask your AI about BioCryst Pharmaceuticals's contract liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude